Deka, Nabajyoti; Bajare, Swapnil; Anthony, Jessy; Nair, Amrutha; Damre, Anagha; Patel, Dharmeshkumar; B.-Rao, Chandrika; Sivaramakrishnan, H.; Mutt, Shivaprakash Jagalur; Wilankar, Chandan; Marita, Rosalind published an article in 2013, the title of the article was Synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives for the treatment of metabolic syndrome.Recommanded Product: 67914-60-7 And the article contains the following content:
Metabolic syndrome is a widely prevalent multifactorial disorder associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic disorder. Thiazolidinediones (TZDs) are potent PPARγ ligands and used as insulin sensitizers in the treatment of type 2 diabetes mellitus. They are potent insulin-sensitizing agents but due to adverse effects like hepatotoxicity, a safer alternative of TZDs is highly demanded. The synthesis of N-(6-(4-(piperazin-1-yl)phenoxy)pyridin-3-yl)benzenesulfonamide derivatives I (R = 2,4-Cl2C6H3, 2,5-(OCH3)2C6H3, 2-thienyl, etc.) an alternate remedy for insulin resistance is reported. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Recommanded Product: 67914-60-7
The Article related to piperazinyl pyridinyl benzenesulfonamide preparation metabolic syndrome, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Recommanded Product: 67914-60-7
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics